Portola Pharmaceuticals portola.com


Public list: BIO 2016 (619) Pharma Startups (4740)

Portola is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options. Portola's current development-stage portfolio consists of three compounds discovered through its internal research efforts and one discovered by Portola scientists during their time at a prior company. In May 2013, Portola Pharmaceuticals went publ...Show all

Portola is a biopharmaceutical company focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who currently have limited or no approved treatment options....Show all

Company (IPO / Went public)

Phone: 650-246-7000

Fax:

270 East Grand Avenue
Suite 22
South San Francisco, 94080
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Portola Pharmaceuticals $442.6M May 22, 2013
See all 29 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Portola Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
Advanced Technology VenturesVenture CapitalMenlo Park, California, United StatesSeries D - II, Series D, Series C - II, Series C, Series B
Alta PartnersVenture CapitalSan Francisco, California, United StatesSeries D - II, Series D, Series C - II, Series C, Series B
AllianceBernsteinAsset/Investment ManagementNew York, New York, United StatesSeries C
Adage Capital ManagementAsset/Investment ManagementBoston, Massachusetts, United StatesSeries C - II
AbingworthVenture CapitalLondon, England, United KingdomSeries C - II, Series C, Series B
See all 27 investors

Competitors

Company Status Description Investors
See all 29 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Benzamides and nicotinamides as syk modulators May 10, 2016 Feb 27, 2018 Patent
Inhibitors of protein kinases Dec 05, 2014 Jan 16, 2018 Patent
Pyridazine compounds as jak inhibitors Feb 12, 2015 Dec 05, 2017 Patent
Substituted pyrimidinyl kinase inhibitors Oct 08, 2013 Jun 13, 2017 Patent
Compounds and methods for purification of serine proteases May 27, 2015 May 09, 2017 Patent
See all 70 patents